Orchid Pharma Share Price Today (ORCHPHARMA)
TODAY IN ONE LINE
ORCHPHARMA is little changed at ₹985.35 on light volume — a quiet consolidation day.
With a market cap of ₹5,000.9 Cr., it trades at a P/E of 243.46. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Orchid Pharma flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●High Promoter HoldingPromoters hold 69.8% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Poor Capital ReturnsLow ROE of 2.1%
- ●Expensive ValuationTrading at a high P/E ratio of 240.7x
- ●Rising Receivables vs SalesReceivables grew 24.0% outpacing sales growth of 12.5%
Latest Orchid Pharma News
What changed recently?
Recent events, corporate actions, and announcements.
Orchid Pharma Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Orchid Pharma Limited, framed against the sector median so the premium or discount is obvious at a glance.
Orchid Pharma Limited trades at a P/E of 243.46× and P/B of 3.88×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Orchid Pharma Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Orchid Pharma Limited — derived from the live tape, not yesterday's close.
Orchid Pharma Limited last traded at ₹985.35 with an intraday range of ₹968.1–₹992 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹985.35| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1043.33 | +57.98 | +5.88% |
| R3 | 1019.43 | +34.08 | +3.46% |
| R2 | 1005.72 | +20.37 | +2.07% |
| R1 | 995.53 | +10.18 | +1.03% |
| PIVOT | 981.82 | -3.53 | -0.36% |
| CURRENT | 985.35 | — | — |
| S1 | 971.63 | -13.72 | -1.39% |
| S2 | 957.92 | -27.43 | -2.78% |
| S3 | 947.73 | -37.62 | -3.82% |
| S4 | 923.83 | -61.52 | -6.24% |
ORCHPHARMA is trading Above CPR, indicating Bullishness
CPR is Average
Day's range: ₹978.1–₹988.65
Trading Inside opening range
Orchid Pharma Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Orchid Pharma Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Orchid Pharma Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹5,000.9 Cr. and reported EPS of ₹4.01.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 922 | 811 ▼ 12.0% |
| Sales Growth YoY %Derived | 12.52% | -12.00% |
| Other Income | 27 | 35 ▲ 28.0% |
| Total Income | 949 | 847 ▼ 10.8% |
| 544 | 526 ▼ 3.4% | |
| Gross ProfitDerived | 378 | 285 ▼ 24.4% |
| Gross Margin %Derived | 40.97% | 35.18% |
| 261 | 244 ▼ 6.2% | |
| EBITDA (Operating Profit)Derived | 117 | 41 ▼ 64.9% |
| OPM %Derived | 12.71% | 5.07% |
| 49 | 42 ▼ 14.2% | |
| Profit Before Tax (PBT) | 96 | 21 ▼ 78.0% |
| -0 | -0 ▲ 1.0% | |
| Effective Tax %Derived | -0.20% | -0.91% |
| Profit/Loss from Discontinued Ops | — | — |
| Total Profit for Period | 100 | 21 ▼ 79.4% |
| Net Profit (Owner's PAT)Derived | 100 | 21 ▼ 79.4% |
| Net Profit Margin %Derived | 10.81% | 2.53% |
| PAT Growth YoY %Derived | 8.13% | -79.38% |
| Earnings Per Share (EPS ₹) | 19.65 | 4.05 ▼ 79.4% |
| Diluted Shares Outstanding (Cr) | 5 | 5 ▲ 0.0% |
| Share of Profit from Associates/JVs | 4 | -1 ▼ 117.0% |
| Other Comprehensive Income (Net of Tax) | -1 | 1 ▲ 219.4% |
| Total Expenses (incl. D&A & Interest) | 854 | 825 ▼ 3.3% |
| Material Cost % of RevenueDerived | 63.50% | 56.99% |
| Employee Cost % of RevenueDerived | 9.37% | 11.27% |
| Other Cost % of RevenueDerived | 18.89% | 18.84% |
| Interest Coverage (x)Derived | 5.68x | 0.43x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 688 | 600 ▼ 12.8% | 508 ▼ 15.3% | 450 ▼ 11.4% | 560 ▲ 24.3% | 666 ▲ 19.0% | 819 ▲ 23.0% | 922 ▲ 12.5% | 811 ▼ 12.0% | |
| Sales Growth YoY %Derived | — | -12.77% | -15.32% | -11.41% | 24.33% | 19.00% | 23.05% | 12.52% | -12.00% | |
| Other Income | 20 | 17 ▼ 16.6% | 24 ▲ 44.7% | 15 ▼ 37.8% | 9 ▼ 40.9% | 19 ▲ 115.8% | 31 ▲ 58.8% | 27 ▼ 11.0% | 35 ▲ 28.0% | |
| Total Income | 708 | 617 ▼ 12.9% | 533 ▼ 13.7% | 465 ▼ 12.6% | 569 ▲ 22.2% | 685 ▲ 20.5% | 850 ▲ 24.1% | 949 ▲ 11.7% | 847 ▼ 10.8% | |
350 | 290 ▼ 17.3% | 243 ▼ 16.0% | 229 ▼ 6.1% | 314 ▲ 37.2% | 385 ▲ 22.7% | 484 ▲ 26.0% | 544 ▲ 12.3% | 526 ▼ 3.4% | ||
| Gross ProfitDerived | 338 | 310 ▼ 8.1% | 265 ▼ 14.7% | 222 ▼ 16.3% | 246 ▲ 11.0% | 281 ▲ 14.3% | 335 ▲ 19.1% | 378 ▲ 12.8% | 285 ▼ 24.4% | |
| Gross Margin %Derived | 49.09% | 51.72% | 52.11% | 49.23% | 43.96% | 42.24% | 40.87% | 40.97% | 35.18% | |
322 | 328 ▲ 2.0% | 290 ▼ 11.6% | 172 ▼ 40.8% | 196 ▲ 14.3% | 198 ▲ 0.6% | 224 ▲ 13.4% | 261 ▲ 16.2% | 244 ▼ 6.2% | ||
| EBITDA (Operating Profit)Derived | 16 | -18 ▼ 216.0% | -25 ▼ 39.9% | 50 ▲ 295.4% | 50 ▼ 0.3% | 84 ▲ 68.5% | 111 ▲ 32.4% | 117 ▲ 5.9% | 41 ▼ 64.9% | |
| OPM %Derived | 2.28% | -3.03% | -5.02% | 11.06% | 8.87% | 12.56% | 13.51% | 12.71% | 5.07% | |
435 | 331 ▼ 23.9% | 130 ▼ 60.7% | 160 ▲ 23.2% | 119 ▼ 25.7% | 126 ▲ 6.0% | 50 ▼ 60.7% | 49 ▼ 1.0% | 42 ▼ 14.2% | ||
| Profit Before Tax (PBT) | -399 | 69 ▲ 117.4% | -131 ▼ 288.8% | -95 ▲ 27.3% | -60 ▲ 36.6% | 55 ▲ 191.4% | 92 ▲ 66.4% | 96 ▲ 3.9% | 21 ▼ 78.0% | |
-46 | — ▲ 100.0% | — | — | — | — | -3 | -0 ▲ 93.8% | -0 ▲ 1.0% | ||
| Effective Tax %Derived | 11.58% | — | — | — | — | — | -3.39% | -0.20% | -0.91% | |
| Profit/Loss from Discontinued Ops | — | — | — | -21 | 58 ▲ 374.8% | -7 ▼ 111.6% | — ▲ 100.0% | — | — | |
| Total Profit for Period | -353 | 69 ▲ 119.7% | -131 ▼ 288.8% | -95 ▲ 27.3% | -2 ▲ 98.0% | 46 ▲ 2473.8% | 92 ▲ 99.0% | 100 ▲ 8.1% | 21 ▼ 79.4% | |
| Net Profit (Owner's PAT)Derived | -353 | 69 ▲ 119.7% | -131 ▼ 288.8% | -95 ▲ 27.3% | -2 ▲ 98.0% | 46 ▲ 2473.8% | 92 ▲ 99.0% | 100 ▲ 8.1% | 21 ▼ 79.4% | |
| Net Profit Margin %Derived | -51.29% | 11.57% | -25.80% | -21.16% | -0.35% | 6.96% | 11.25% | 10.81% | 2.53% | |
| PAT Growth YoY %Derived | — | 119.68% | -288.84% | 27.33% | 97.95% | 2,473.84% | 98.99% | 8.13% | -79.38% | |
| Earnings Per Share (EPS ₹) | -39.65 | 7.80 ▲ 119.7% | -32.11 ▼ 511.7% | -28.55 ▲ 11.1% | -0.48 ▲ 98.3% | 11.35 ▲ 2464.6% | 18.17 ▲ 60.1% | 19.65 ▲ 8.1% | 4.05 ▼ 79.4% | |
| Diluted Shares Outstanding (Cr) | 9 | 9 ▲ 0.0% | 4 ▼ 54.1% | 4 ▲ 0.0% | 4 ▲ 0.0% | 4 ▲ 0.0% | 5 ▲ 24.3% | 5 ▲ 0.0% | 5 ▲ 0.0% | |
| Share of Profit from Associates/JVs | — | — | — | — | — | -2 | -3 ▼ 34.6% | 4 ▲ 234.5% | -1 ▼ 117.0% | |
| Other Comprehensive Income (Net of Tax) | 1 | 1 ▲ 21.8% | -2 ▼ 323.7% | 1 ▲ 132.9% | 1 ▲ 114.1% | -0 ▼ 112.6% | -0 ▼ 88.6% | -1 ▼ 122.8% | 1 ▲ 219.4% | |
| Total Expenses (incl. D&A & Interest) | 1,107 | 548 ▼ 50.5% | 664 ▲ 21.2% | 561 ▼ 15.5% | 629 ▲ 12.2% | 630 ▲ 0.2% | 758 ▲ 20.3% | 854 ▲ 12.6% | 825 ▼ 3.3% | |
| Material Cost % of RevenueDerived | 49.64% | 43.81% | 46.36% | 54.57% | 60.87% | 60.98% | 64.48% | 63.50% | 56.99% | |
| Employee Cost % of RevenueDerived | 12.54% | 13.71% | 16.68% | 14.91% | 11.31% | 9.81% | 8.50% | 9.37% | 11.27% | |
| Other Cost % of RevenueDerived | 34.27% | 41.04% | 40.45% | 23.26% | 23.79% | 19.87% | 18.87% | 18.89% | 18.84% | |
| Interest Coverage (x)Derived | -0.39x | -494.49x | -36.41x | -1.15x | -1.17x | 0.89x | 4.73x | 5.68x | 0.43x |
Orchid Pharma segment analysis : revenue and profit mix.
Disclosed business segments at Orchid Pharma with their share of revenue and profit, switchable between consolidated and standalone reporting.
Orchid Pharma discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Orchid Pharma Limited.
Our AI distills the core fundamental drivers supporting Orchid Pharma Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Orchid Pharma Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Strong promoter holding at 69.84% signals insider confidence and long-term commitment.
Conservative debt-to-equity ratio of 0.0028 reflects minimal financial leverage risk.
Operating margin of 19.54% TTM demonstrates efficient core operational performance.
Positive operating cash flow of ₹118.64 Cr supports liquidity and operational needs.
Global export presence across 40 countries diversifies revenue streams internationally.
Key Risks.
Latest quarterly revenue declined 29.20% YoY, indicating significant demand weakness.
Latest quarterly profit fell 49.20% YoY, raising earnings volatility concerns.
Net profit margin of 2.51% TTM is lowest among peers, severely limiting profitability.
P/E ratio of 240.74× is extremely elevated, suggesting severe overvaluation.
Negative free cash flow in recent periods; capex consistently exceeds operating cash generation.
Flip Conditions.
Valuation risk. a P/E above 316 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
Orchid Pharma Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Orchid Pharma Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Orchid Pharma Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Orchid Pharma Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Orchid Pharma Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Orchid Pharma Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Orchid Pharma Limited stood at 47.1% of traded volume, against a 20-day average of 36.9%.
Orchid Pharma announcements: results, concalls, ratings, M&A.
Filings Orchid Pharma sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Orchid Pharma files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 107 documents below.
Updates
Orchid Pharma Limited has informed the Exchange regarding 'Intimation regarding investor roadshow '.
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Orchid Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Record Date
Orchid Pharma Limited has informed the Exchange that Record date for the purpose of Merger/HiveOff is 23-Jul-2026.
Amendment to AOA/MOA
Orchid Pharma Limited has informed the Exchange regarding the Amendment to AOA/MOA of the company.
Outcome of Board Meeting
Outcome of the Board Meeting: Noting the effect of Scheme of Amalgamation
Investor decks & rating reports.
Investor Presentation
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation
Investor Presentation
Investor Presentation
Analysts/Institutional Investor Meet/Con. Call Updates
Orchid Pharma dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Orchid Pharma has declared, sequenced by announce and record date.
Orchid Pharma corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Orchid Pharma Limited: business, sector, key facts.
What Orchid Pharma Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Orchid Pharma Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: ORCHPHARMA, BSE: 524372.
Orchid Pharma Limited is an Indian pharmaceutical company specializing in the development, production, and marketing of a diverse range of pharmaceutical products. Their core offerings encompass active pharmaceutical ingredients (APIs), bulk drugs, finished dosage formulations (FDFs), and nutraceuticals. This broad portfolio allows them to cater to various sectors within the pharmaceutical industry, demonstrating a robust and diversified business model.
Within their API portfolio, Orchid Pharma focuses on key therapeutic areas. A significant portion of their business involves cephalosporins, both oral and injectable forms, used extensively in treating bacterial infections. They also manufacture veterinary products and non-antibiotic APIs, expanding their reach into different animal health and human health applications. This strategic diversification minimizes reliance on any single product or market segment.
Orchid Pharma boasts a multi-therapeutic presence across several key medical areas. These include anti-infectives (a significant area given their cephalosporin expertise), anti-inflammatory drugs, central nervous system medications, and cardiovascular drugs. The addition of nutraceuticals showcases a strategic move into the growing health and wellness market. Their product range further extends to other oral and sterile formulations, covering a wide spectrum of healthcare needs.
Beyond their manufacturing and marketing activities, Orchid Pharma offers specialized services in new drug discovery systems and pharmaceutical research and development. This positions them not only as a producer but also as a valuable partner for other pharmaceutical companies seeking innovative solutions and development expertise. Their international presence is also noteworthy, with exports to approximately 40 countries, indicating a significant global reach and market penetration.
Established in 1992 and currently a subsidiary of Dhanuka Laboratories Limited, Orchid Pharma (formerly Orchid Chemicals & Pharmaceuticals Limited) has a long history in the industry. Based in Narsinghpur, India, the company's integrated approach combining API manufacturing, formulation development, and global marketing contributes to its position as a significant player in the Indian and international pharmaceutical markets.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Orchid Pharma Limited (ORCHPHARMA).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Orchid Pharma Limited (ORCHPHARMA)?
The current share price of Orchid Pharma Limited (ORCHPHARMA) is ₹985.35. Today, the stock has declined by ₹2.60 (0.26%), trading in a range of ₹968.1 to ₹992. The stock opened at ₹987.3 with a trading volume of 43,875 shares.
02Is Orchid Pharma Limited stock a good investment for long-term?
Orchid Pharma Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹5,000.9 crores, P/E ratio of 243.46, ROE of 2.12%, and ROCE of 2.64%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Orchid Pharma Limited stock?
The 52-week high price of Orchid Pharma Limited (ORCHPHARMA) is ₹1,119.8, while the 52-week low is ₹480. Currently trading at ₹985.35, the stock is 79.0% away from its 52-week low and 12.0% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Orchid Pharma Limited stock at the current price?
Whether to buy Orchid Pharma Limited stock at ₹985.35 depends on multiple factors. The stock is currently trading with a P/E ratio of 243.46 and P/B ratio of 3.88. Today's performance shows a loss of 0.26%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Orchid Pharma Limited and when is the next dividend?
Orchid Pharma Limited offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹985.35, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Orchid Pharma Limited?
Orchid Pharma Limited's key financial metrics include: P/E Ratio: 243.46, P/B Ratio: 3.88, ROE: 2.12%, ROCE: 2.64%, Dividend Yield: 0.00%, EPS: ₹4.01, Book Value: ₹253.98, and Debt-to-Equity: 0.28. The company's market cap stands at ₹5,000.9 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Orchid Pharma Limited stock performing today in the market?
Orchid Pharma Limited stock opened at ₹987.3 and is currently trading at ₹985.35, showing a decline of ₹2.60 (0.26%). The intraday high is ₹992 and low is ₹968.1. The trading volume stands at 43,875 shares, indicating moderate market participation today.
08What is the P/E ratio of Orchid Pharma Limited and what does it indicate?
Orchid Pharma Limited has a Price-to-Earnings (P/E) ratio of 243.46, which means investors are willing to pay ₹243.46 for every ₹1 of earnings. With an EPS of ₹4.01, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Orchid Pharma Limited (ORCHPHARMA) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.